Screener
Veracyte VCYT Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Veracyte in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Veracyte’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 8:07 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001384101-26-000031
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Depreciation and amortization | 5,430 | 5,362 |
| Loss on disposal of property, plant and equipment | 366 | — |
| Stock-based compensation | 12,761 | 10,958 |
| Deferred income taxes | (10) | 15 |
| Noncash lease expense | 732 | 904 |
| Revaluation of acquisition-related contingent consideration | (350) | (1,954) |
| Effect of foreign currency on operations | (80) | (1,585) |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Veracyte's stock-based comp?
- Veracyte (VCYT) reported stock-based comp of $12.76M in Q1 2026.
- How has Veracyte's stock-based comp changed year-over-year?
- Veracyte's stock-based comp increased by 16.5% year-over-year, from $10.96M to $12.76M.
- What is the long-term trend for Veracyte's stock-based comp?
- Over 4 years (2021 to 2025), Veracyte's stock-based comp has grown at a 18.0% compound annual growth rate (CAGR), from $22.52M to $43.6M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Veracyte's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude